Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of changes to the Covid-19 vaccination eligibility criteria on (a) clinically vulnerable people who qualified for vaccination in Autumn 2024 and (b) levels of hospital capacity during the 2025–26 cold and flu season.

The Government’s policy on groups eligible for vaccination programmes is based on the advice of the independent expert body, the Joint Committee on Vaccination and Immunisation (JCVI). Over time, the risk from COVID-19 has reduced across the United Kingdom population, through exposure to the virus, changes in the virus and vaccination.

The JCVI carefully considered the latest evidence on the risk of illness, serious disease in specific groups, as well as cost-effectiveness analysis, to provide the Government with advice on the autumn 2025 programme. The evidence indicates that whilst the risk from COVID-19 is now much lower for most people, adults aged 75 years old and over, residents in care homes for older adults, and those who are immunosuppressed are those at highest risk of serious COVID-19 disease. A more targeted vaccination programme, aimed at individuals, with a higher risk of developing serious disease, and where vaccination was considered potentially cost-effective, was advised for autumn 2025.

Whilst current COVID-19 vaccines provide good protection against hospitalisation and/or death for those at highest risk, they provide very limited protection against acquiring COVID-19 infection or mild illness, meaning any potential public health benefit of reducing transmission is much less evident.

Long term health consequences following COVID-19 infection, including post-COVID syndromes, such as long COVID, have been discussed at meetings of the JCVI. It remains uncertain whether getting extra COVID-19 vaccine doses has any effect on the chances of developing long COVID, how it progresses, or how it affects people.

The JCVI has proactively published an updated list of Research Recommendations, encouraging future investigations on the exploration of data and evidence on the benefit of vaccination amongst post-COVID syndromes, and those with underlying medical conditions who are not currently eligible.

The JCVI keeps all vaccination programmes under review. Accordingly, the Government will consider any additional advice from the JCVI in due course. Further information on the details of the modelling and analysis considered are within the 2025 and spring 2026 advice, on the GOV.UK website.

Information is collected on hospital bed occupancy and on the reason for hospital admissions. It is, however, not possible to determine which admissions associated with COVID-19 were for individuals who were eligible for vaccination in autumn 2024 but no longer eligible in autumn 2025.